Risk for dementia, ischemic stroke, mortality lower with GLP-1 receptor agonists in type 2 diabetes, obesity

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other antidiabetic drugs, according to a study published online July 15 in JAMA Network Open.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup